K36 Therapeutics
Manufacturing · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1 Main St, Cambridge, Massachusetts, 021...Website
www.k36tx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About K36 Therapeutics
K36 Therapeutics is a biotechnology company with a focus on cancer treatments with headquarters in Cambridge, MA.Explore more
K36 Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is K36 Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if K36 Therapeutics had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at K36 Therapeutics
Earning: See what the market has to say on K36 Therapeutics recently announced quarterly report
K36 Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check if K36 Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Check out if K36 Therapeutics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when K36 Therapeutics launches new products
Funding: Get notified immidiatlly once K36 Therapeutics has new funding data
Recommended Actions
Reach out to Masked Content who joined K36 Therapeutics as Masked Content
Find 3 more new buyers
Compare Similar Companies to K36 Therapeutics
Compare insights from companies similar to K36 Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
K36 Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
K36 Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about K36 Therapeutics.
K36 Therapeutics financials insights
Gather financial insights about K36 Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series A
$30M
2023
Series B
$70M
K36 Therapeutics Tech Stack
A closer look at the technologies used by K36 Therapeutics
See more technologies
Most Recent Scoops
Event
Person-Based
Events, Podcast
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
New Hire
Executive Move
New Hire
Executive Move
K36 Therapeutics News & Media
K36 Therapeutics Completes Dosing of First Cohort in Phase 1 Clinical Trial of KTX-2001 in Prostate Cancer, Announces New CMO
KTX-2001 being evaluated both as a monotherapy and in combination with darolutamide in metastatic castration-resistant prostate cancer (mCRPC) Shinta Cheng, M.D., Ph.D., joins company as Chief Medical Officer CAMBRIDGE, Mass., Feb. 5, 2026 /PRNewswire/ -- K36 Therapeutics, Inc. ("K36"), a...K36 Therapeutics announces presentation of First-in-Human Clinical Data for Gintemetostat (KTX-1001) Demonstrating Target Engagement and Clinical Activity in Multiple Myeloma at ASH 2025 and the Appointment of Dr. Shinta Cheng, M.D., Ph.D., as Chief Medical Officer
First-in-human data highlights safety, pharmacodynamics, and single-agent activity supporting MMSET/NSD2 inhibition in heavily pre-treated multiple myeloma patients Shinta Cheng, M.D., Ph.D., joins K36 to drive clinical development of lead programs and oncology pipeline expansion...K36 Therapeutics to Present New Preclinical Data Supporting Ongoing Phase 1 Clinical Trial of KTX-1001 at the 22nd Annual International Myeloma Society Meeting
Two posters highlight the differentiated approach of KTX-1001 as a potential first-in-class therapy for patients with relapsed or refractory multiple myeloma who have exhausted standard options CAMBRIDGE, Mass., Sept. 18, 2025 /PRNewswire/ -- K36 Therapeutics, Inc. ("K36"), a privately...K36 Therapeutics Provides Clinical Update on KTX-1001 in Multiple Myeloma
Initial patients dosed in multiple cohorts of the Phase 1 dose-expansion study assessing KTX-1001 in combination with standard of care and mezigdomide for t(4;14) multiple myeloma Company enters into supply agreement with Bristol Myers Squibb for the novel investigational treatment...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding K36 Therapeutics
Sign Up For FreeTo access detailed company insights
K36 Therapeutics is a biotechnology company with a focus on cancer treatments with headquarters in Cambridge, MA.... Read More
